載入中
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
一般交易時段
US$3.14
+US$0.03 · +0.96%
盤中時間採用ET。市場資料可能有所延遲。
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
日內區間
目前US$3.14
52週區間
目前US$3.14
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
45
合理估值
情緒
51
多空交錯
風險
66
高風險
動能
19
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
日內區間
目前US$3.14
52週區間
目前US$3.14
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 1.2萬 USD | — | — | — | — |
| 毛利 | −1.2萬 USD | — | — | — | — |
| 研究與開發 | 714.4萬 USD | 472.5萬 USD | 222.5萬 USD | 74.5萬 USD | 4069 USD |
| 銷售、一般及管理費用 | 989萬 USD | 686.3萬 USD | 524.9萬 USD | 124.5萬 USD | 1359.02萬 USD |
| 營業費用 | 1702.2萬 USD | 1158.8萬 USD | 1203萬 USD | 199萬 USD | 1359.43萬 USD |
| 利息收入 | 31.9萬 USD | 35.4萬 USD | 12.7萬 USD | — | — |
| 利息支出 | — | 17.6萬 USD | 7.9萬 USD | — | 21.81萬 USD |
| 折舊和攤銷 | 1.2萬 USD | 18.3萬 USD | 8.1萬 USD | — | — |
| 營業利益 | −1703.4萬 USD | −1158.8萬 USD | −1203萬 USD | −199萬 USD | −1359.43萬 USD |
| 淨利 | −1671.5萬 USD | −1141萬 USD | −1542.6萬 USD | −199萬 USD | −1332.87萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年6月24日 | 1:21 | — | — |
已生效 2026年6月24日
1:21
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
